 |
|
| Blog results | Results 1 - 10 of about 172 for reboxetine pfizer. (0.23 seconds) |
| Sorted by relevance Sort by date |
| 18 Jul 2009 by Neuroskeptic Furthermore, 6 potentially relevant trials were identified that could not be included because no full publication existed and the manufacturer of reboxetine (Pfizer) refused to provide full information on all trials with reboxetine. ... Neuroskeptic - http://neuroskeptic.blogspot.com/ - References |
| 8 Jul 2009 by admin the multinational drug company pfizer has once again been caught in the act of concealing research data. this time the accusation comes, not from researchers, but from the institute for quality and efficiency in health care (iqwig) ... Indian IT News - http://www.indianitworld.com/ |
| 26 Nov 2009 by pillscribe Reboxetine was approved in Germany in December 1997. Pfizer also applied for approval in the USA but this was evidently not granted in 2001. By early 2007, reboxetine was licensed worldwide in over 60 countries. Reboxetine (Edronax) is ... DWS Pill Scribe - http://www.dancewithshadows.com/pillscribe/ |
| 5 Dec 2009 by Editor In the case of reboxetine, IQWiG abandoned its analysis of the study data that was publicly available at that time, because it was evident that the manufacturer, Pfizer, was concealing almost two thirds of all data collected in trials ... The Health Gazette - http://the-health-gazette.com/ |
| 15 Jun 2008 by linzworld According to FibroAction, a major trial of the drug Reboxetine for Fibromyalgia Syndrome (Fibro) is currently recruiting patients in the USA and Canada. The 14 week randomised double-blind Phase III trial, sponsored by Pfizer, ... Living with Fibromyalgia - http://linzworld.wordpress.com/ |
| 12 Jun 2009 by Jim Edwards Pfizer has apparently held back clinical trial data for its anti-depressant reboxetine (known in Germany as Edronax) from IQWiG, Germany's drug-benefit assessment agency, leading the agency to declare "no proof of benefit" in its ... Pharma RSS Feed - http://industry.bnet.com/pharma/ |
| 3 Feb 2010 by admin Pfizer took shiley in 1979 at the antidepressant of its early group reaction, identifying the bjork-shiley syndrome neurotransmitter, male enhancement viagra. Lexapro out of blood level, responds your sign unfortunately include people ... Jordan Mendoza's diary - http://jochenmoser.com/ - References |
| 5 Mar 2008 This group includes three Phase III programs, valuable potential new indications for market-leaders Celebrex and Lyrica, and trials of S,S reboxetine for fibromyalgia. In addition, Pfizer's nine pain compounds in development include the ... Drugs.com - Pharma News - http://www.drugs.com/news.html |
| 27 Jun 2009 by edhayes the pharmaceutical company pfizer is concealing data on the effect of a drug (edronax® containing the agent reboxetine) for the treatment of depression. despite repeated requests by the institute for quality and efficiency in health ... Edmund's Page - http://edhayes.com/ |
| 28 Nov 2009 by editor This has been brought to a head by the publication of the final report on three antidepressants which was greatly hindered by Pfizer. For a long time, the manufacturer refused to make information on trials available to IQWiG. ... hclindia.com - http://www.hclindia.com/ [ More results from hclindia.com ] |
Stay up to date on these results:
| Google Home - About Google Blog Search Beta - Information for Blog Authors |
